Year: 2023
Type: editorial
Abstract: Complex patient-specific manufacturing and variable potency due to poor T-cell fitness limit advances in autologous chimeric antigen receptor T therapies and support the potential attractiveness of having potent immune effector cell therapy that is readily available “off the shelf.” Edited by Associate Editor Helen Heslop and authored by leading experts, this review series focuses on several types of banked allogeneic immune cell therapies under development, highlighting their attributes and speculating on their anticipated future place in the therapeutic armamentarium.
Source: Blood
Author: Helen E. Heslop
Institution: Baylor College of Medicine
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4313643559